Cartesian Therapeutics (RNAC) Payables (2016 - 2025)
Historic Payables for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $2.2 million.
- Cartesian Therapeutics' Payables rose 33036.75% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 33036.75%. This contributed to the annual value of $288000.0 for FY2024, which is 9085.71% down from last year.
- Per Cartesian Therapeutics' latest filing, its Payables stood at $2.2 million for Q3 2025, which was up 33036.75% from $454000.0 recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Payables peaked at $3.2 million during Q4 2023, and registered a low of $154000.0 during Q2 2021.
- Its 5-year average for Payables is $1.0 million, with a median of $517000.0 in 2024.
- Within the past 5 years, the most significant YoY rise in Cartesian Therapeutics' Payables was 97191.01% (2024), while the steepest drop was 9085.71% (2024).
- Cartesian Therapeutics' Payables (Quarter) stood at $224000.0 in 2021, then soared by 41.07% to $316000.0 in 2022, then surged by 896.84% to $3.2 million in 2023, then plummeted by 90.86% to $288000.0 in 2024, then skyrocketed by 672.57% to $2.2 million in 2025.
- Its last three reported values are $2.2 million in Q3 2025, $454000.0 for Q2 2025, and $2.1 million during Q1 2025.